Antiangiogenesis: a possible treatment option for prostate cancer? Clin Genitourin Cancer. 2005; 4:197-202. https://doi. org/10.3816/CGC.2005.n.033.Longoria RL, Cox MC, Figg WD: Antiangiogenesis: a possible treatment option for prostate cancer?. [Review] [86 refs]. Clinical Genitourinary ...
Research published in JAMA Oncology on Thursday revealed that higher doses of radiation don’t improve survival for many prostate cancer patients, compared with standard radiation treatment. “Over the past two decades radiation oncologists have become adept at treating men to these higher radiation ...
Prostate cancer, the leading incidence of cancer in American males, is a disease in which treatment of non-localized tumors remains largely unsuccessful. These cancers lose expression of an arginine synthesis enzyme, argininosuccinate synthetase (ASS), and are susceptible to arginine deprivation by argi...
Prostate cancer feeds on testosterone. The drug, enzalutamide, targets the androgen receptor on the cancer cell that is like a tiny landing pad for male hormones. It closes down the runway and starves the cell of testosterone and other male hormone-like substances. Some cancer cells may die; ...
For low risk prostate cancer, this figure was 2.4 per cent in the surveillance group (95% CI...
Expectant management: an option for localized prostate cancer Localized prostate cancer demonstrates tremendous heterogeneity in the natural history of the disease. To this end, although prostate cancer may be present... M,A,Khan,... - 《Prostate Cancer & Prostatic Diseases》 被引量: 34发表: ...
Radical prostatectomy: an option for high-risk prostate cancer.doi:10.1155/2012/410246Introduction. High-risk prostate cancer represents a therapeutic challenge. The role of radical prostatectomy (RP) in patients with extreme PSA values is under discussion. Material and Methods. We retrospectively ...
How would you say sipuleucel-T has improved the treatment of patients with prostate cancer? For one, it gives patients another option. When this drug first came out, there really were not a lot of options for men with metastatic castration-resistant prostate cancer [CRPC]...
During the press conference, Janssen Korea also recognized the pivotal role Korean researchers played in the TITAN trial, which was the basis for the approval of Erleada, and said it would continue to collaborate with Korean researchers throughout the entire prostate cancer treatment cycle. ...
Expectant management as an option for men with stage Tic prostate cancer: A preliminary study The outcome of patients selecting observation of clinical stage T1c prostate cancer is unknown. A total of 101 men with clinical stage T1c prostate cancer ... JL Mohler,BT Williams,JA Freeman - 《...